Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIGURE 3.
FIGURE 3.

Characterization of MDS-defining splicing programs. (A) PCA identified a 204-event panel (MDS-Dx) that differentiates MDS from healthy samples (both bone marrow and peripheral blood were included, while healthy lineage sorted samples were excluded). (B) Unsupervised hierarchical clustering of MDS and healthy samples with the MDS-Dx panel. (C) Pathway analysis of the MDS-Dx panel using Ingenuity IPA.

This Article

  1. Published in Advance August 4, 2016, doi: 10.1261/rna.056101.116 RNA 22: 1535-1549

Current Issue

  1. July 2026, 32 (7)
  1. Current Issue
  1. Alert me to new issues of RNA